Carbetocin
| 證據等級: L5 | 預測適應症: 2 個 |
目錄
Carbetocin: From Postpartum Haemorrhage Prevention to Isotretinoin-like Syndrome
One-Sentence Summary
Carbetocin is a synthetic long-acting oxytocin analogue (oxytocin receptor agonist), clinically established for prevention of uterine atony and postpartum haemorrhage following caesarean section. The TxGNN model predicts it may be effective for Isotretinoin-like Syndrome, however no clinical trials and no published literature currently support this direction — the prediction is driven solely by knowledge graph topology.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Prevention of uterine atony and postpartum haemorrhage (oxytocin receptor agonist, established pharmacological class) |
| Predicted New Indication | Isotretinoin-like Syndrome |
| TxGNN Prediction Score | 99.15% |
| Evidence Level | L5 |
| Saudi Arabia Market Status | ✗ Not Marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Carbetocin is a long-acting synthetic analogue of endogenous oxytocin, acting selectively on the oxytocin receptor (OXTR). Its pharmacological action is concentrated on two domains: peripheral smooth muscle contraction of the uterus (driving its use in postpartum haemorrhage prevention), and central nervous system modulation of social behaviour and bonding through the oxytocin pathway.
Isotretinoin-like syndrome (retinoic acid embryopathy) arises from excessive retinoic acid exposure during embryonic development, causing aberrant cranial neural crest cell migration and differentiation via the RAR/RXR nuclear receptor signalling pathway. This is a developmental teratogenicity syndrome — not a disease state that involves oxytocin receptor biology in any known mechanistic framework. There is no documented biochemical crossover between OXTR signalling and retinoic acid/RAR/RXR pathways in the current literature.
The very high TxGNN score (99.15%) therefore reflects knowledge graph topological proximity — likely mediated through shared network neighbours in the disease–gene–protein interaction graph — rather than a direct biological hypothesis. In the absence of any experimental, preclinical, or mechanistic evidence, this must be classified as a distant model-driven prediction with very low clinical credibility.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Saudi Arabia Market Information
Carbetocin is not currently registered or authorised by SFDA in Saudi Arabia. No product licence records are available.
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: Despite a high TxGNN prediction score, the mechanistic pathway of carbetocin (OXTR agonism → uterine contraction / CNS oxytocin modulation) has no known intersection with isotretinoin-like syndrome pathophysiology (excess retinoic acid → RAR/RXR-mediated cranial neural crest disruption). With zero supporting clinical trials or literature, and evidence classified at L5, advancing this candidate would require first establishing a plausible biological hypothesis — which does not currently exist.
Note: The second-ranked prediction (Goodman syndrome / ACPS IV, TxGNN score 99.06%) faces an identical evidence vacuum and an equally distant mechanistic rationale (RAB23/Hedgehog pathway vs. OXTR), and is likewise recommended Hold pending any hypothesis generation.
To proceed, the following is needed:
- A credible mechanistic hypothesis linking OXTR signalling to retinoic acid embryopathy or neural crest biology (e.g., oxytocin–retinoic acid crosstalk in neural development)
- Preclinical in vitro or in vivo data demonstrating any relevant biological effect of carbetocin in a teratogenicity or neural crest model
- Full mechanism of action data from DrugBank (DG002: currently missing)
- SFDA package insert safety data including warnings and contraindications (DG001: currently missing)
- Review of whether isotretinoin-like syndrome is a viable therapeutic target at all (it is a teratogenicity outcome syndrome, not a chronic treatable disease state)
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.